Who are Standard of Care for GVHD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MC, Stempeucel®, Cx601, JOINTSTEM, Rexlemestrocel-L + HA Mixture, Cellgram-LC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-of-care-for-gvhd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Standard of Care for GVHD — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standard of Care for GVHD (Standard of Care for GVHD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mesenchymal stem cell therapy. Area: Immunology.

phase 3 Mesenchymal stem cell therapy Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Standard of Care for GVHD (Standard of Care for GVHD) — Mesoblast, Inc.. Rexlemestrocel-L is a mesenchymal stem cell therapy that modulates the immune system to treat graft-versus-host disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Standard of Care for GVHD TARGET	Standard of Care for GVHD	Mesoblast, Inc.	phase 3	Mesenchymal stem cell therapy
MC	MC	Aivita Biomedical, Inc.	marketed	Mesenchymal stem cell therapy
Stempeucel®	Stempeucel®	Cell Biopeutics Resources Sdn Bhd	marketed	Allogeneic mesenchymal stem cell therapy
Cx601	Cx601	Tigenix S.A.U.	phase 3	Allogeneic mesenchymal stem cell therapy
JOINTSTEM	JOINTSTEM	R-Bio	phase 3	Autologous mesenchymal stem cell therapy
Rexlemestrocel-L + HA Mixture	Rexlemestrocel-L + HA Mixture	Mesoblast, Ltd.	phase 3	Allogeneic mesenchymal stem cell therapy
Cellgram-LC	Cellgram-LC	Pharmicell Co., Ltd.	phase 3	Allogeneic mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mesenchymal stem cell therapy class)

Aivita Biomedical, Inc. · 1 drug in this class
EHL Bio Co., Ltd. · 1 drug in this class
Mesoblast, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard of Care for GVHD — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-of-care-for-gvhd. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab